belviq 10 mg (lorcaserin hcl)
belviq 10 mg (lorcaserin hcl) is a serotonin 2C receptor agonist indicated for the treatment of chronic weight management in adults with a body mass index (BMI) of 30 or greater (obese) as an addition to a reduced-calorie diet and exercise.
belviq 10 mg
belviq 10 mg (lorcaserin) is a weight loss medication approved by the Food and Drug Administration (FDA). If you are obese or overweight and have a weight-related medical condition, it may help you to lose weight.
Introduction belviq 10 mg :
BELVIQ (lorcaserin HCI) CIV was approved for use by the FDA in 2013 on the basis of three pivotal clinical trials which used lorcaserin 10 mg immediate release tablets administered twice daily.
BELVIQ XR (lorcaserin HCI) CIV was approved in 2016 on the basis of bioequivalence data comparing the 20mg XR formulation once daily versus lorcaserin 10 mg twice daily.
Mechanism of Action:
BELVIQ and BELVIQ XR is believed to decrease food consumption and promote satiety by selectively activating serotonin 2C (5-HT2c) receptors in the hypothalamus. The exact mechanism of action is not known.
BELVIQ and BELVIQ XR is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
- 30 kg/m2 or greater, or
- 27 kg/m2 or greater with at least one weight-related comorbid condition